Skip to content

Viking Therapeutics

US · VKTX #2352 by market cap Listed 2015
24.77 -1.07 -4.14%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:56

✦ Quant Ownership Signal how this is computed

Mixed / stable
  • The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
  • Total institutional ownership (as a % of shares) was little changed.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
66.26% -0.08pp
Institutions
514 +1
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund45.67%
Hedge Fund11.11%
Public Company5.65%
Private Company2.83%
Individual/Insider2.25%
Government Pension Fund0.45%
Family Office/Trust0.21%
VC/PE Fund0.15%
Insurance Company0.13%
Other31.54%

Top holders as of 2026-09-30

FMR 7.69% · 9.81M sh
BlackRock 4.83% · 6.16M sh
State Street Global Advisors 4.35% · 5.55M sh
Vanguard Capital Management, LLC 4.23% · 5.39M sh
Vanguard Portfolio Management, LLC 3.70% · 4.72M sh
Two Sigma Investments, LP 3.09% · 3.94M sh
Morgan Stanley 2.81% · 3.58M sh
Morgan Stanley Investment Management Inc. 2.81% · 3.58M sh
Brian Lian 1.74% · 2.22M sh
Columbia Management Investment Advisers, LLC 1.85% · 2.16M sh
Geode Capital Management, LLC 1.73% · 2.20M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 36 buys · 14 sells

NameRoleStake
Brian Lian Chief Executive Officer 1.74%
Marianne Mancini Former Chief Operating Officer 0.25%
Matthew Foehr Independent Director 0.10%
Gregory Zante Chief Financial Officer 0.09%
Lawson MacArtney Independent Chairperson 0.04%
Charles Rowland Independent Director 0.02%
J. Singleton Independent Director 0.01%
Neil Aubuchon Former Chief Commercial Officer 0.00%
Sarah Rouan Independent Director 0.00%
Hubert Chen Chief Medical Officer --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-07-31 Dorothy Gemmell Director Other Acquisition +6,333 --
2026-07-31 Dorothy Gemmell Director Other Derivative Acquisition +40,800 $31.74
2026-07-28 Gregory Zante Chief Financial Officer Open Market Disposition -21,217 $33.47
2026-07-28 Brian Lian Chief Executive Officer Open Market Disposition -148,517 $33.32
2026-07-28 Marianne Mancini Former Chief Operating Officer Open Market Disposition -18,217 $33.47
2026-07-27 Gregory Zante Chief Financial Officer Other Acquisition +31,667 --
2026-07-27 Brian Lian Chief Executive Officer Other Acquisition +221,667 --
2026-07-27 Marianne Mancini Former Chief Operating Officer Other Acquisition +31,667 --
2026-05-31 Hubert Chen Chief Medical Officer Other Derivative Acquisition +190,000 $31.27
2026-03-09 Neil Aubuchon Former Chief Commercial Officer Open Market Acquisition +4,475 $33.50
2026-01-11 Neil Aubuchon Former Chief Commercial Officer Other Derivative Acquisition +180,000 $31.76
2026-01-04 Gregory Zante Chief Financial Officer Other Acquisition +41,000 --
2026-01-04 Gregory Zante Chief Financial Officer Open Market Disposition -57,661 $32.09–34.24
2026-01-04 Brian Lian Chief Executive Officer Other Acquisition +78,400 --
2026-01-04 Brian Lian Chief Executive Officer Open Market Disposition -233,409 $32.29–35.07
2026-01-04 Marianne Mancini Former Chief Operating Officer Other Acquisition +41,000 --
2026-01-04 Marianne Mancini Former Chief Operating Officer Open Market Disposition -57,661 $32.29–35.07
2026-01-01 Matthew Foehr Independent Director Other Acquisition +3,150 --
2026-01-01 Matthew Foehr Independent Director Derivative Exercise and Sale -16,000 $3.33–35.11
2026-01-01 Matthew Foehr Independent Director Other Derivative Acquisition +20,400 $35.42

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:56:05 · For reference only, not investment advice and not tailored to your situation.

Viking Therapeutics discussion 0 comments

Add a comment